ArticleFrontiers in oncology2022

Lenvatinib combined with anti-PD-1 antibodies plus transcatheter arterial chemoembolization for neoadjuvant treatment of resectable hepatocellular carcinoma with high risk of recurrence: A multicenter retrospective study.

Jun-Yi Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.